Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
study id #: NCT03153319
condition: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
status: Recruiting
purpose:Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
intervention: Adalimumab Injection [Humira], Saline Solution for Injection
results: https://clinicaltrials.gov/ct2/show/results/NCT03153319
last updated: February 26, 2022
-
Oral Treatment for Mucopolysaccharidosis VI: Outcomes of the First Phase Iia Study With OdiparcilMucopolysaccharidosis (MPS) disorders ar...
-
The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-A...Nonrandomized studies are usually exclud...
-
Long-Term Evolution of Mucopolysaccharidosis Type I in Twins Treated With Enzyme Replacement Therapy Plus Hematopoie...Mucopolysaccharidoses (MPSs) are a heter...
-
Walla Al-Hertani, MD, MS, FRCPC, FCCMG, FACMGDr. Walla Al-Hertani is a Medical Bioche...
-
Condyle Morphology Among Patients With Mucopolysaccharidosis: An Observational Study of Panoramic RadiographsMucopolysaccharidoses (MPS) are a group ...
-
Real-World Data Assessment of Safety of Home-Based and Hospital/Outpatient-Based laronidase Enzyme Replacement Thera...Enzyme replacement therapy (ERT) is avai...
-
A Multicenter Open-Label Extension Study of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Typ...Sanfilippo syndrome type A (mucopolysacc...